GV-100
Sponsor
Gilva Therapeutics
Trial Name
First-in-Human SAD/MAD
Start Date
2026-06
Est. Completion
2027-03
Participants
80
Location
Undisclosed
NCT ID
NCT07788014Mechanism
Undisclosed oral drug candidate developed for ADPKD.
Detailed article coming soon. See the trial details above for current information.
Disclaimer: This information is for educational purposes only and is not medical advice. Clinical trial information is based on publicly available data from ClinicalTrials.gov and published research. Consult your nephrologist before making treatment decisions.